登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、募集资金基本情况 根据中国证券监督管理委员会于2022年9月1日签发的证监许可[2022]2009号文《关于核准粤海永顺泰集 团股份有限公司首次公开发行股票的批复》，粤海永顺泰集团股份有限公司(以下简称"公司"或"本公 司")于2022年11月向社会公众发行人民币普通股125,432,708股，每股发行价格为人民币6.82元，募集资 金总额为人民币855,451,068.56元。扣除发行费用人民币61,205,647.11元后，实际募集资金净额为人民币 794,245,421.45元，上述资金于2022年11月8日到位，业经普华永道中天会计师事务所(特殊普通合伙)予 以验证并出具普华永道中天验字(2022)第0862号《验资报告》。 二、募集资金专户开立情况 为规范公司募集资金的存放、使用和管理，切实保护投资者权益，公司根据《上市公司募集资金监管规 则》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第1号一一主板上市公 司规范运作》等有关法 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会于2022年9月1日签发的证监许可[2022]2009号文 《关于核准粤海永顺泰集团股份有限公司首次公开发行股票的批复》，粤海永顺泰 集团股份有限公司(以下简称"公司"或"本公司")于2022年11月向社会公众发行 人民币普通股125,432,708股，每股发行价格为人民币6.82元，募集资金总额为人民 币855,451,068.56元。扣除发行费用人民币61,205,647.11元后，实际募集资金净额 为人民币794,245,421.45元，上述资金于2022年11月8日到位，业经普华永道中天会 计师事务所(特殊普通合伙)予以验证并出具普华永道中天验字(2022)第0862号《验 资报告》。 证券代码：001338 证券简称：永顺泰 公告编号：2026-001 粤海永顺泰集团股份有限公司 二、募集资金专户开立情况 关于部分募集资金专户销户完成的公告 信银行股份有限公司广州新城国际支行)的管理机构，负责与外部签署协议，因此由 中信银行股份有限公司广州分行签署上述《募 ...

Market Overview - The agricultural processing sector increased by 0.15% on January 5, with Morning Glory Biological leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Stock Performance - Morning Glory Biological (300138) closed at 12.83, with a rise of 3.38% and a trading volume of 75,200 shares, amounting to 95.67 million yuan [1] - Other notable performers included: - ST Zhongji (000972) at 4.03, up 2.81% with a trading volume of 258,900 shares [1] - Jinlongyu (300999) at 29.37, up 2.19% with a trading volume of 123,900 shares [1] - Daodaoquan (002852) at 10.73, up 1.71% with a trading volume of 44,300 shares [1] Capital Flow - The agricultural processing sector saw a net inflow of 30.45 million yuan from main funds, while retail funds experienced a net outflow of 11.92 million yuan [2] - The main funds' net inflow and outflow for specific stocks included: - Huadao Industrial (600191) with a net inflow of 24.94 million yuan [3] - Guannong Co. (600251) with a net inflow of 17.58 million yuan [3] - Yongshuntai (001338) with a net inflow of 9.82 million yuan [3]

证券日报网讯 12月30日，永顺泰发布公告称，截至2025年12月29日，公司存放在上海浦东发展银行股 份有限公司广州东山支行的募集资金专项账户余额为0元。为方便公司统一管理，减少管理成本，根据 相关规定，公司已办理完成上述募集资金专户的销户手续，公司、保荐机构中信建投证券股份有限公司 与上海浦东发展银行股份有限公司广州东山支行签订的相关《募集资金三方监管协议》相应终止。 （编辑 任世碧） ...

粤海永顺泰集团股份有限公司 关于部分募集资金专户销户完成的公告 证券代码：001338 证券简称：永顺泰 公告编号：2025-045 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会于2022年9月1日签发的证监许可[2022]2009号文《关于 核准粤海永顺泰集团股份有限公司首次公开发行股票的批复》，粤海永顺泰集团股份有限 公司(以下简称"公司"或"本公司")于2022年11月向社会公众发行人民币普通股 125,432,708股，每股发行价格为人民币6.82元，募集资金总额为人民币855,451,068.56元 。扣除发行费用人民币61,205,647.11元后，实际募集资金净额为人民币794,245,421.45元 ，上述资金于2022年11月8日到位，业经普华永道中天会计师事务所(特殊普通合伙)予以验 证并出具普华永道中天验字(2022)第0862号《验资报告》。 二、募集资金专户开立情况 为规范公司募集资金的存放、使用和管理，切实保护投资者权益，公司根据《上市公 司募集资金监管规则》《深圳证券交易所股票上 ...

Group 1 - Hubei Yihua has received acceptance from the Shenzhen Stock Exchange for its application to issue convertible bonds to unspecified objects [1] - Tongye Technology plans to acquire 91.69% of Beijing Silingke Semiconductor Technology Co., Ltd. for a total price of 561 million yuan [2] - Heng Rui Medicine has signed an exclusive licensing agreement with Hansoh Pharmaceutical, which includes a payment of 30 million yuan and potential milestone payments up to 190 million yuan [3] Group 2 - Jun Da Co. announced that its strategic cooperation framework agreement with Shangyi Optoelectronics will not significantly impact its current operating performance [4] - Jinchuan Group's wholly-owned subsidiary is jointly investing in a venture capital partnership to invest in Shanghai Gesi Information Technology Co., Ltd. [5] - Baili Tianheng plans to apply for the registration of debt financing tools not exceeding 10 billion yuan [6] Group 3 - Yuanda Environmental Protection announced the resignation of its chairman Chen Bin due to work changes [7] - Aerospace Development reported that its subsidiary's revenue accounted for less than 1% of the total revenue in the first three quarters of 2025 [8] - ST Huluwawa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission for information disclosure violations [10] Group 4 - Jia Mei Packaging confirmed that it has no plans for significant changes to its main business or for a reverse merger in the next 36 months [11] - Wangfujing has won the bid for the duty-free project at Beijing Capital International Airport, with a guaranteed operating fee of 113 million yuan for the first year [12] - Siwei Liekong has suspended trading due to potential changes in control [13] Group 5 - Zhongchao Holdings announced a tax payment and late fee totaling 8.2881 million yuan [14] - Yongshuntai plans to conduct foreign exchange derivative trading with a total amount not exceeding 1.7 billion yuan in 2026 [15] - Guojin Securities has been approved to publicly issue company bonds not exceeding 25 billion yuan [16] Group 6 - Jincheng Pharmaceutical's subsidiaries are required to pay a total of 21.5968 million yuan in taxes and late fees [17] - China Shenhua's subsidiary has successfully completed the trial operation of its power generation unit [19] - Yijing Optoelectronics has received a hearing notice regarding the inability to advance its photovoltaic project [20] Group 7 - Jiga Development has received debt waivers totaling 378 million yuan from its controlling shareholder and related parties [21] - ST Lutong plans to apply to the Shenzhen Stock Exchange to revoke other risk warnings after a shareholder repaid funds [22] - Xin'ao Co. is progressing with the privatization of Xin'ao Energy and has completed significant asset restructuring foreign exchange registration [23]

Group 1 - The company held its 23rd meeting of the second board on December 26, 2025, with all 8 directors present, and the meeting complied with relevant laws and regulations [2][5] - The board approved several proposals, including the revision of the company's information disclosure management measures and investor relations management measures [3][4][6][8] - All proposals were passed unanimously with 8 votes in favor, and no votes against or abstentions [5][8] Group 2 - The company plans to use idle self-owned funds for entrusted financial management in 2026, with a total amount not exceeding RMB 600 million, allowing for cyclical use within the specified period [60][63] - The investment will be limited to low-risk, capital-preserving financial products, and the investment period is from January 1, 2026, to December 31, 2026 [61][64] - The board authorized the management to implement the entrusted financial management matters [65] Group 3 - The company intends to conduct foreign exchange derivative trading in 2026, with a total transaction amount not exceeding RMB 1.7 billion, aimed at hedging against foreign exchange risks [72][73] - The trading period for the foreign exchange derivatives will also be from January 1, 2026, to December 31, 2026, with a maximum duration of 12 months for the derivatives [74] - The board has authorized the management to implement the foreign exchange derivative trading matters [75] Group 4 - The company will hold its first extraordinary shareholders' meeting of 2026 on January 30, 2026, with the meeting's agenda already approved by the board [79][84] - The meeting will allow for both on-site and online voting, ensuring participation from all eligible shareholders [82][84] - The registration for the meeting will take place on January 29, 2026, with specific requirements for different types of shareholders [85][86]

证券日报网讯 12月28日，永顺泰发布公告称，公司第二届董事会第二十三次会议审议通过《关于审议 等6项制度的议案》《关于审议等3项制度的议案》《关于公司及子公司2026年度开展外汇衍生品交易业 务的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 12月28日，永顺泰发布公告称，公司及子公司拟开展的外汇衍生品交易业务涉及品种为 金融机构提供的普通远期、窄区间远期、封顶远期、期权和掉期等产品。公司及子公司2026年度拟开展 的外汇衍生品交易业务累计发生额不超过人民币17亿元（或等值外币），额度使用期限自2026年1月1日 至 2026年12月31日，期限内任一时点的外汇衍生品交易金额不应超过已审议额度，衍生产品的期限不 超过12个月。 （编辑 王江浩） ...

Core Viewpoint - The company has approved a proposal for foreign exchange derivative trading activities for the year 2026, with a total amount not exceeding 1.7 billion yuan (or equivalent foreign currency) [1] Group 1 - The approved trading amount for foreign exchange derivatives is capped at 1.7 billion yuan [1] - The usage period for this trading limit is from January 1, 2026, to December 31, 2026 [1] - At any point during the specified period, the total amount of foreign exchange derivative transactions, including any related amounts from reinvested earnings, must not exceed the approved limit [1] Group 2 - The derivatives involved in these transactions will have a maximum duration of 12 months [1]